Testis Tümörlü Hastalarda Tümör Grade İle Preoperatif Nötrofil Lenfosit Oranının İlişkisi

Öz

Amaç:Bu çalışmada testis tümörü sebebi ile opere edilen hastalarda nötrofil-lenfosit oranının (NLO) postoperatif tümör evresini belirlemedeki etkisinin değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntem:Ocak 2006- Eylül 2017 yılları arasında primer testis tümörü nedeniyle orşiektomi yapılan 17 hastanın verileri retrospektif olarak incelendi. Çalışmaya alınan hastaların yaşı, tümör histolojik tipi, patolojik evresi, serum nötrofil sayısı, serum lenfosit sayısı ve nötrofil-lenfosit oranları kayıt edildi. T1 evre testis tümörü olan hastalar grup 1, T2 evre ve üzeri testis tümörü olan hastalar ise grup 2 olarak sınıflandırıldı. Bağımsız gruplarda Levenee testi kullanılarak her iki grubun nötrofil-lenfosit oranları istatistiksel olarak karşılaştırıldı.

Bulgular: Hastaların ortalama yaşları, ortalama kan nötrofil sayıları, lenfosit sayıları ve nötrofil-lenfosit oranları sırasıyla 30.47±16.83 yıl, 6.1189±0.242 (K/uL), 2.4165±0.106 (K/uL) ve 2.88±1.8 idi. Histopatolojik incelemede, 3 (%17.64) hastada saf seminom, 11 (%64.7) hastada mikst germ hücreli tümör, 2 (%11.74) hastada yolk sac tümörü ve 1 (%5.88) hastada lenfoma olduğu belirlendi. Hastaların 9 (%52.94)’unda T1, 8 (%47.05)’inde T2 ve üzeri hastalık izlendi. Grup 1 ve 2'nin NLO’ları sırasıyla, 2.72 (SD:1.862) ve 3.05 (SD:1.913) idi. NLO açısından değerlendirildiğinde iki grup arasında istatistiksel olarak anlamlı fark izlenmedi. (p:0.723)

Sonuç: Çalışmada elde edilen sonuçlara göre NLO, preoperatif olarak testis tümörü evresini öngörememektedir. Ancak sonuçların desteklenmesi için daha fazla hasta sayılı ve prospektif verilere ihtiyaç vardır.

Anahtar Kelimeler

• Nötrofil-lenfosit oranı,testis tümörü,evresi

The Relationship Between Tumor Grade And Preoperatif Neuthrophil Lymphocyte Ratio In Patients with Tecticular Tumor

Öz

Aim:  The effect of serum parameters on survival and tumor stage still being investigated for cancer patients. In this study, we aimed to evaluate the effect of neutrophil-lymphocyte ratio (NLR) in determining the postoperative tumor stage in patients with testicular tumors.

Material and Methods: The data of 17 patients who were performed orchiectomy for primary testicular tumor at our clinic between January 2006 and Sempember 2017 was evaluated retrospectively. Patients’ age, histological type of tumor, pathologic stage, serum neutrophil, lymphocytecounts NLR values were recorded. Patients were divided into two groups as Group 1 and 2, which contain stage T1 and stage T≥2 diseases, respectively. NLR of both groups were compared statistically using the Levenee test for independent samples.

Results: For all patients, mean age, mean serum neutrophil, lymphocyte value and mean NLR were 30.47±16.83 years, 6.1189±0.242 (K/uL), 2.4165±0.106 (K/uL) and 2.88±1.8 respectively. Pathologic examination revealed pure seminoma in 3 (%17.64) patients, mixed germ cell tumor in 11 (%64.7) patients, yolk sac tumor in 2 (%11.74)  patients, lymphoma in 1 (%5.88) patient. T 1 disease and T ≥2 disease were revealed in 9 (%52.94) and 8 (%47.05) of the patients. The NLR for groups 1 and 2 were 2.72 (SD:1.862) and 3.05 (SD:1.913) respectively. There was no statistically significant difference between both groups regarding the NLR. (p:0.723)

Conclusion: NLR could not predict the pathological stage of testicular tumor preoperatively. However, high patient volume and prospective trails are needed to support our results.

Anahtar Kelimeler

• Neutrophil-lymphocyte ratio,testicular tumor,stage

Kaynakça

1. 1. Steele GS, Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology. 1997;11:717-729
2. 2. Khan O, Protheroe A. Testis cancer. Postgrad Med J. 2007; 83: 624-632
3. 3. Deotra A, Mathur DR, Vyas MC. A 18 years study of testicular tumours in Jodhpur, Western Rajasthan. Postgrad Med J 1994; 40: 68-70
4. 4. Richie JP, Steele GS. Testis tumors. Walsh PC, Retik AB, Vaughan ED, Wein AJ: Campbell’s Urology, 8th ed., Philadelphia. WB Saunders. Vol 4, Chapt. 46: 2876-2919
5. 5. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K et al. Guidelines on Testicular Cancer: 2015 Update Eur Urol 2015; 68(6): 1054-1068
6. 6. Bahrami A, Ro JY, Ayala AG. An overview of testicular germ cell tumors. Arch Pathol Lab Med. 2006;131:1267-1280.
7. 7. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011;60:304-319.
8. 8. NCCN Clinical practice guidelines in Oncology Testicuar Cancer version. 2.2011

9. 9. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444
10. 10. Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKeeRF, et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring system in patients undergoing curative resection for colon cancer. Br J Cancer. 2009;100:701-6.
11. 11. Coussens LM, Werb Z. Inflammation and Cancer Nature. 2002;420(6917):860-867
12. 12. Parkin DM, Bray F, Ferlay J, Pisani P. 2002 Global cancer statistics. CA Cancer J Clin. 2005;55(2):74-108
13. 13. Enserink M. A push to fight cancer in the developing world. Science 2011; 331(6024): 1548-1550
14. 14. Petel, P.R., Richardeon RL, Kvole L.: Sycnchromuous and metachronous bilateral testicular tumor. Cancer. 1990;65:1-4
15. 15. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. WHO Classification of Tumours. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press, Lyon. 2004;217-277
16. 16. Walschaerts M, Muller A, Auger J, Bujan L, Guerin JF, Lannou DL, et al. Environmental, occupational and familial risks for testicular cancer: a hospital-based case-control study. Int J Androl. 2007;30:222-229.
17. 17. Ginsburg J. Unanswered questions in carcinoma of testis. Lancet. 1997;349(9068):1785-6.
18. 18. Dieckmann KP, Pichmeier U. The prevelance of familial testicular cancer. Cancer. 1997;80(10):1954-60.
19. 19. Hoei-Hansen CE, Holm M, Rajpert-De Meyts E, et al. Carcinoma in situ testis the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol. 2005;16(6):863-8.
20. 20. Cheville JC. Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am. 1999;26:595-609.
21. 21. Brierley JE. et al., The TNM Classification of malignant tumors 8th edition. 2016.
22. 22. Higashi k, Ueda y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al.18f-fdg uptake as s biologic factor for reccurence in patients with germ cell tumors. Canser 2000; 88: 162-168
23. 23. Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88(1):162-8.
24. 24. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539–45.
25. 25. Cho H, Hur HW, Kim SW, Kim SH, KimJH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predict survival after treatment. Cancer Immunol Immunother. 2009;58(1):15-23.
26. 26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
27. 27. Ohno Y, Nakashima J, Ohori M, Tanaka A, Hashimoto T, Gondo T, et al. Clinicalvariables for predicting metastatic renal cell carcinoma patients who might not benefit fromcytoreductive nephrectomy: neutrophil to lymphocyte ratio and performance status. Int JClin Oncol. 2014;19(1):139-145.
28. 28. Ozyalvaclı G, Yesil C, Kargı E, Kızıldag B, Kilitci A, Yılmaz F. Diagnostic and Prognostic Importance of the Neutrophil Lymphocyte Ratio in Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2014;10363-6.
29. 29. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55-60.
30. 30. Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med. 2007;167:1837-44.
31. 31. Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E, Ünal D. J Turgut Ozal Med Cent. 2013:20(3):243-5.
32. 32. Hamidi N, Süer E, Gökçe Mİ, Bedük Y. Van Tıp Dergisi Medical Journal. 2017;24(2):106-9.